This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment of MODY

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

treatment

seek expert advice.

GCK - MODY

  • general consensus is that the majority of these patients do not require treatment since insulin or oral hypoglycaemic agents has little effect on glycemia in this group
  • however in pregnancy insulin may be required to prevent excess fetal growth

HNF1A-MODY and HNF4A-MODY

  • low dose sulfonylureas are recommended as first line treatment for patients with HNF1A/HNF4A-MODY, however most patients will progress to insulin treatment with time
  • a short-acting sulfonylurea such as nateglinide may sometimes be used as an alternative

Reference:

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.